Samsung Biopharma signs $1.29 billion contract with US pharmaceutical company
September 10, 2025
Source: drugdu
99
Samsung Biologics announced on September 9th that it had signed a contract manufacturing organization (CMO) contract worth US$1.29464 billion (approximately 1.8001 trillion won) with a US pharmaceutical company. This contract, the second-largest order in the company's history, runs until December 31, 2029. The client and product names are not being disclosed due to confidentiality clauses.
Source：https://finance.eastmoney.com/a/202509093508399792.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
